• Explore /
  • Poster
  • / FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase II RAMIRIS Study of the AIO.

FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase II RAMIRIS Study of the AIO.

Abstract Poster

Authors

null

Sylvie Lorenzen

Klinikum rechts der Isar, Technische Universität München, III, Medizinische Klinik und Poliklinik, Munich, Germany

Sylvie Lorenzen , Peter C. Thuss-Patience , Claudia Pauligk , Eray Goekkurt , Thomas Jens Ettrich , Florian Lordick , Michael Stahl , Peter Reichardt , Martin Soekler , Daniel Pink , Stephan Probst , Axel Hinke , Thorsten Oliver Goetze , Salah-Eddin Al-Batran

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT03081143

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4514)

DOI

10.1200/JCO.2020.38.15_suppl.4514

Abstract #

4514

Poster Bd #

122

Abstract Disclosures

Similar Posters

First Author: Sylvie Lorenzen

First Author: Sylvie Lorenzen

First Author: Peter C. Thuss-Patience

First Author: Rika Saito